Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q1 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2023 Net Income-$43.86M-$43.86MN/M vs Q1 2023 EPS Diluted$0.72$0.72N/M vs Q1 2023 Operating Income-$47,774,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 9, 2024 · 39 d after period end